|
Market Closed -
Warsaw S.E.
11:55:49 2026-09-03 EDT
|
5-day change | 1st Jan Change | ||
| 6.440 PLN | +0.62% |
|
+5.23% | -2.42% |
| 08-03 | Molecure Receives Positive IDMC Recommendation To Continue The KITE Clinical Trial Without Changes To The Study Protocol | CI |
| 05-19 | Molecure Q1 net loss 4.1 mln zlotys | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 35.31M | - | ||||
| 68.87B | |||||
| 65.29B | |||||
| 27.65B | - | ||||
| 26.08B | - | ||||
| 25.77B |
- Stock Market
- Stocks
- MOC Stock
- Charts Molecure S.A.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
